Study on the Management of Heavy Menstrual Bleeding by Low Dose Dexamethasone
- 1. Associate Professor, Dep. of Obstetrics and Gynaecology, Pacific Institute of Medical Sciences Umarda, Udaipur, Rajasthan
Description
Introduction: Menstruation that is so severe it interferes with a woman’s physical, emotional, social, and material well-being is referred to as heavy menstrual bleeding (HMB). Estimates place the prevalence of excessive menstrual bleeding in impoverished countries at 4-9%. It has figured out the causes of HMB and around 48% of patients that are sent to secondary care do not have any evident pathology. Aims and objectives: The purpose of this research study has been explored to the management of heavy menstrual bleeding by low dose dexamethasone. Methods: This prospective Randomized Controlled Trial enrolled 100 female patients with heavy menstrual bleeding (HMB) from May 2022 to April 2023. Patients were randomly assigned to receive either placebo or dexamethasone, a synthetic glucocorticoid, in different dosages (0.4 mg, 0.8 mg, 1 mg, 1.2 mg, 1.5 mg, or 1.8 mg) during the luteal phase of three menstrual cycles. Menstrual blood loss was evaluated using a lab-validated method. Inclusion and exclusion criteria were applied, and statistical analysis was performed using SPSS 25 software, including Chi-square and ANOVA tests. Significance level was set at p<0.05. Results: The researcher was divided into two different groups of patients such as placebo and dexamethasone with 20 and 80 patients respectively. Furthermore, the age categories of patients are from 22 to 56 years old. Again, the mean blood loss during menstruation is high around 136.5 mL of dexamethasone. The greatest impact was seen at a 25 mL reduction in menstrual blood loss with the 1/8 mg total daily dose, with a 95% credible interval of 1 to 49 mL. The posterior odds for any benefit over placebo, or at least a 10 mL benefit, for this dose, were 0.98 and 0.89, respectively. Conclusion: The study has concluded that 0.8mg of dexamethasone taken twice daily for 5 days during the luteal phase of the menstrual cycle would reduce menstrual blood does volume.
Abstract (English)
Introduction: Menstruation that is so severe it interferes with a woman’s physical, emotional, social, and material well-being is referred to as heavy menstrual bleeding (HMB). Estimates place the prevalence of excessive menstrual bleeding in impoverished countries at 4-9%. It has figured out the causes of HMB and around 48% of patients that are sent to secondary care do not have any evident pathology. Aims and objectives: The purpose of this research study has been explored to the management of heavy menstrual bleeding by low dose dexamethasone. Methods: This prospective Randomized Controlled Trial enrolled 100 female patients with heavy menstrual bleeding (HMB) from May 2022 to April 2023. Patients were randomly assigned to receive either placebo or dexamethasone, a synthetic glucocorticoid, in different dosages (0.4 mg, 0.8 mg, 1 mg, 1.2 mg, 1.5 mg, or 1.8 mg) during the luteal phase of three menstrual cycles. Menstrual blood loss was evaluated using a lab-validated method. Inclusion and exclusion criteria were applied, and statistical analysis was performed using SPSS 25 software, including Chi-square and ANOVA tests. Significance level was set at p<0.05. Results: The researcher was divided into two different groups of patients such as placebo and dexamethasone with 20 and 80 patients respectively. Furthermore, the age categories of patients are from 22 to 56 years old. Again, the mean blood loss during menstruation is high around 136.5 mL of dexamethasone. The greatest impact was seen at a 25 mL reduction in menstrual blood loss with the 1/8 mg total daily dose, with a 95% credible interval of 1 to 49 mL. The posterior odds for any benefit over placebo, or at least a 10 mL benefit, for this dose, were 0.98 and 0.89, respectively. Conclusion: The study has concluded that 0.8mg of dexamethasone taken twice daily for 5 days during the luteal phase of the menstrual cycle would reduce menstrual blood does volume.
Files
IJPCR,Vol15,Issue5,Article26.pdf
Files
(307.7 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:d42bcaec4ed8051e61327cbc9ca1b76e
|
307.7 kB | Preview Download |
Additional details
Dates
- Accepted
-
2023-04-23
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/15/IJPCR,Vol15,Issue5,Article26.pdf
- Development Status
- Active
References
- 1. Santer M, Warner P, Wyke S. A Scottish postal survey suggested that prevailing clinical pre-occupation withheavy periods does not reflect the epidemiology of reported symptoms and problems. J Clin Epidemiol. 2005; 58:1206–10. 2. Shapley P, Jordan K, Croft PR. An epidemiological survey of symptoms of menstrual loss in the community. BJGP. 2004;54:359–63. 3. Bhattacharya S, Middleton L, Tsourapas A, Lee A, Champaneria R, Daniels J, et al. Hysterectomy, endometrial ablation and Mirena(R) for heavy menstrual bleeding: a systematic review of clinical effectiveness and cost-effectiveness analysis. Health Technol Assess. 2011;15:1–252. 4. Royal College of Obstetricians and Gynaecologists. London school of hygiene & tropical medicine, ipsos MORI. national heavy menstrual bleeding audit: first annual report. London: RCOG Press; 2011. 5. Harlow SD, Campbell OM. Epidemiology of menstrual disorders in developing countries: a systematic review. BJOG. 2004;111:6–16. 6. National Institute for Clinical Excellence. Heavy menstrual bleeding. NICE Clinical Guideline CG44; 2007. 7. Anand E, Kumar P, Unisa S, Singh J. Neglect of menstrual disorders in reproductive health care in India: a population-based survey. Women's Reprod. Health. 2018;5 (4):287–300. 8. Sriprasert I, Pakrashi T, Kimble T, Archer DF. Heavy menstrual bleeding diagnosis and medical management. Contracept Reprod Med. 2017;2:20. 9. Kaloo P, Davies S. Case discussion: heavy menstrual bleeding in primary care and beyond. Br J Family Med. 2014;2 https://www.bjfm.co.uk/casediscussion-heavymenstrual-bleedingin-primary-care-and-beyond. 10. Period poverty Scotland https://www.economist.com/britain/20 20/02/27/freeperiod-products-inscotland, Accessed Sep. 2020. 11. Munro MG, Critchley HOD, Fraser IS, for the FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynecol Obstet. 2018;143:393–408. 12. K A Matteson D, D Rahn TL, Wheeler II, Casiano E, Siddiqui NY, Harvey HS, for the Society of Gynecologic Surgeons Systematic Review Group. Non-surgical management of heavy menstrual bleeding: a systematic review and practice guidelines. Obstet Gynecol. 2013;121(3):632–43. 13. Royal College of Obstetricians and Gynaecologists. London school of hygiene & tropical medicine, IPSOS MORI. National heavy menstrual bleeding audit: third annual report. London: RCOG Press; 2013. 14. Rae M, Mohamad A, Price D, Hadoke PW, Walker BR, Mason JI, et al. Cortisol inactivation by 11betahydroxysteroid dehydrogenase-2 may enhance endometrial angiogenesis via reduced thrombospondin-1 in heavy menstruation. J Clin Endocrinol Metab. 2009;94:1443–50. 15. Krams M, Sharma A, Dragalin V, Burns DD, Fardipour P, Padmanabhan SK, et al. Adaptive approaches in clinical drug development. opportunities and challenges in design and implementation. Pharm Med. 2009; 23(3):139–48. 16. Chataway J, Nicholas R, Todd S, Miller DH, Parsons N, Valdes-Marquez E, et al. A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis. Mult Scler. 2011;17:81–8. 17. Souverain PC, Berard A, van Staa TP, Cooper C, Leufkens HGM, Walker BR. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population-based casecontrol study. Heart. 2004;90:859–65. 18. van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk offractures. J Bone Miner Res. 2000; 15:993–1000. 19. Kemp MW, Newnham JP, Challis JG, Jobe AH, Stock SJ. The clinical use of steroids in pregnancy. Hum. Reprod. Update. 2016;22(2):240–59. 20. Warner P, Critchley HO, Lumsden MA, Campbell-Brown M, Douglas A, Murray G. Referral for menstrual problems: cross sectional survey of symptoms, reasons for referral, and management. BMJ. 2001;323:24–8. 21. Santer M, Wyke S, Warner P. What aspects of periods are most bothersome for women reporting heavy menstrual bleeding? Community survey and qualitative study. BMC Womens Health. 2007;7:8. 22. Lukes AS, Muse KN, Richter HE, Moore KA, Patrick DL. Estimating a meaningful reduction in menstrual blood loss for women with heavy menstrual bleeding. Curr Med Res Opin. 2010;26:2673–8. 23. Lukes AS, Moore KA, Muse KN, Gersten JK, Hecht BR, Edlund M, et al. Tranexamic acid treatment for heavy menstrual bleeding A randomized controlled trial. Obstet Gynecol. 2010;116:865–75 24. Warner P, Whitaker LHR, Parker RA, Weir CJ, Douglas A, Hansen CH, Madhra M, Hillier SG, Saunders PTK, Iredale JP, Semple S, Slayden OD, Walker BR, Critchley HOD. Low dose dexamethasone as treatment for women with heavy menstrual bleeding: A response-adaptive randomised placebocontrolled dose-finding parallel group trial (DexFEM). E Bio Medicine. 2021 Jul;69:103434. 25. Warner P, Weir CJ, Hansen CH, Douglas A, Madhra M, Hillier SG, Saunders PT, Iredale JP, Semple S, Walker BR, Critchley HO. Low-dose dexamethasone as a treatment for women with heavy menstrual bleeding: protocol for response-adaptive randomised placebo-controlled dosefinding parallel group trial (DexFEM). BMJ Open. 2015 Jan 14;5(1):e006837. 26. Tamubango Kitoko, H. Accouchement prématuré aux cliniquesuniversitaires de Lubumbashi de 2011-2019: fréquence et prise en charge. Journal of Medical Research and Health Sciences, 2023; 6(2): 2457–2470.